Rigel Pharmaceuticals (RIGL) investor relations material

Commercial execution and product growth

• Three approved products in the U.S.: TAVALISSE, REZLIDHIA, and GAVRETO, each showing strong sales growth and market expansion.

• Net product sales reached $64 million last quarter, a 65% increase year-over-year, with TAVALISSE leading at $44.7 million, up 70%.

• GAVRETO sales increased from $7 million to $11.1 million per quarter post-acquisition; REZLIDHIA grew 50% to $8.3 million.

• TAVALISSE adoption expanded to earlier lines of therapy, improving response rates and durability.

• International partnerships have secured approvals in Europe, Asia, Korea, and Mexico, with further expansion ongoing.

Financial performance and discipline

• Maintained profitability through controlled SG&A expenses despite product portfolio growth.

• Generated $60 million in cash year-to-date and $27.9 million in net income last quarter.

• Raised revenue guidance to $285–$290 million for the year, with $225–$230 million from product sales.

• Achieved 32% average annual growth over three years, guiding to 55–59% growth this year.

• Cash generation funds R&D, especially for pipeline programs like R289.

Pipeline development and strategic focus

• Actively seeking to in-license late-stage, synergistic hematology and oncology assets to leverage existing infrastructure.

• R289 (IRAK1/4 inhibitor) targets low-risk MDS, with promising early data and fast-track/orphan designations.

• Phase 1b study for R289 completed dose escalation; expansion phase enrolling, with data expected in a year and registrational study planned for 2027.

• Olutasidenib (REZLIDHIA) being studied in multiple new indications through collaborations with MD Anderson and MyeloMatch.

• Additional pipeline includes a partnered RIP1 inhibitor with Eli Lilly for immune diseases, currently in phase 2 for rheumatoid arthritis.